These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 21692679)
1. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator. Fondell A; Edwards K; Unga J; Kullberg E; Park JW; Gedda L J Drug Target; 2011 Nov; 19(9):846-55. PubMed ID: 21692679 [TBL] [Abstract][Full Text] [Related]
2. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. Gedda L; Fondell A; Lundqvist H; Park JW; Edwards K J Nucl Med; 2012 Mar; 53(3):480-7. PubMed ID: 22323773 [TBL] [Abstract][Full Text] [Related]
3. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702 [TBL] [Abstract][Full Text] [Related]
4. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. Shmeeda H; Tzemach D; Mak L; Gabizon A J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844 [TBL] [Abstract][Full Text] [Related]
5. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648 [TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
7. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607 [TBL] [Abstract][Full Text] [Related]
8. A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Ickenstein LM; Edwards K; Sjöberg S; Carlsson J; Gedda L Nucl Med Biol; 2006 Aug; 33(6):773-83. PubMed ID: 16934696 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. Laginha KM; Moase EH; Yu N; Huang A; Allen TM J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132 [TBL] [Abstract][Full Text] [Related]
10. Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. Hare JI; Moase EH; Allen TM J Drug Target; 2013 Jan; 21(1):87-96. PubMed ID: 23039213 [TBL] [Abstract][Full Text] [Related]
11. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo. Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440 [TBL] [Abstract][Full Text] [Related]
12. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361 [TBL] [Abstract][Full Text] [Related]
13. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094 [TBL] [Abstract][Full Text] [Related]
14. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938 [TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192 [TBL] [Abstract][Full Text] [Related]
16. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461 [TBL] [Abstract][Full Text] [Related]
17. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Xiong S; Yu B; Wu J; Li H; Lee RJ Biomed Pharmacother; 2011 Feb; 65(1):2-8. PubMed ID: 21177069 [TBL] [Abstract][Full Text] [Related]
18. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
20. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]